Coronary Artery Disease (CAD) is the medical condition caused due to diseased or damaged blood vessels that supply blood, oxygen, and nutrients, to the heart. CAD is characterized through cholesterol plague deposition within the arteries, resulting into inflammation. Rising plague deposition eventually narrows coronary arteries, which in turn decreases the blood flow towards the heart. Reduction in blood flow for the heart results in breath shortness along with chest pain causing heart attack after a complete blockage. CAD is caused through smoking, high cholesterol, high blood pressure, insulin resistance or diabetes, hypertension or sedentary lifestyle. Other factors associated with coronary artery disease are obesity, high stress, unhealthy diet, and physical inactivity. Coronary artery disease could be prevented through maintaining healthy diet, consuming low salt vegetables and fruits and low fat, stress management, and physical activity. Treatment of CAD includes ACE inhibitors, cholesterol modifying medications, Aspirin, Calcium channel blockers, Ranolazine, and beta blockers. Surgeries conducted for treating coronary artery disease are Nitroglycerin, coronary artery bypass, and Angioplasty.
Global Coronary Artery Disease Therapeutics Market Drivers:-
The global coronary artery disease therapeutics market is expected to register robust growth, owing to robust drug pipeline during the forecast period (2018-2026). For instance, tablets of hydroxychloroquine sulfate sponsored by Xi’an Jiaotong University, China, the first affiliated hospital is within its fourth clinical trials phase. The drug suppresses the symptoms of coronary artery disease. University Health Network, Toronto-sponsored Atorvastatin has completed clinical trials of phase two, in 2014. The drug decreases the risk of myocardial infraction and heart attack. University hospital Inselsiptal, Berne, sponsored PADMA 28, has completed clinical trials of phase 2 in 2013, the drug have a beneficial effect upon arterial system, blood inflammatory markers, and the autonomic nervous system in patients having coronary artery disease.
Moreover, approval of novel drugs of coronary artery disease is another factor expected to drive of the global coronary artery disease therapeutics market growth over the forecast period. For instance, the U.S. Food and Drug Administration (FDA), in 2016, approved Yosprala (Aspirin and Omeprazole) from the Canada-based Aralez Pharmaceuticals, this drug is used to prevent cardiovascular diseases. In 2015, the U.S. FDA approved Repatha by Amgen Inc. This drug is used to treat high cholesterol. The U.S. Food and Drug Administration (FDA), in 2015, approved Prestalia from Symplmed Pharmaceuticals LLC, the drug is used for the treatment of hypertension in people enduring from heart disorders. Marina Biotech Inc. acquired Prestalia in later 2017.
However, high price of novel drugs is expected to restrain of the global coronary artery disease therapeutics market growth over the forecast period. For instance, the Entresto was introduced by the U.S.-based Novartis, indicated to prevent heart failures. Its 60 tablets are worth US$ 492, which is expensive to middle and low income population.
Ask for PDF sample copy of the Coronary Artery Disease Therapeutics market report @ https://www.coherentmarketinsights.com/insight/request-pdf/1799
Global Coronary Artery Disease Therapeutics Market Regional Analysis:-
North America is expected to account for the highest share in the global coronary artery disease therapeutics market, owing to coronary artery disease high prevalence. As per the Centers for Disease Control and Prevention (CDC) survey in 2015, coronary heart diseases cause death of over 370,000 individuals annually within the U.S., from which over 92% experienced chest pain as the major symptom. As per the American College of Cardiology, conducted study in 2017, over 790000 individuals experienced heart attack in the U.S. annually, out of which over 47% were reported of having hypertension, and over 34% were reported of having high blood pressure. Hence, high chronic diseases prevalence are expected to propel growth of the global coronary artery disease therapeutics market over the forecast period. Asia Pacific region is projected to register robust growth owing to approvals by the U.S. Food and Drug Administration (FDA) for the generic drugs. For instance, the India-based Lupin, in 2017, received approval of the U.S. FDA for launching Nadolol Tablets’ generic version, indicated to treat angina pectoris and hypertension.
Major players functioning in the global coronary artery disease therapeutics market are Astra Zeneca, Novartis, Gilead, Pfizer, Merck & Co, Bayer, Glaxo Smith Kline, Mylan N.V., and others
Global Coronary Artery Disease Therapeutics Market Taxonomy:-
Based on Drug Type:
- Calcium Channel Blockers
- ACE Inhibitors
Based on Distribution Channel:
- Online Pharmacies
- Retail Pharmacies
Based on geography:
- North America
- Latin America
- Asia Pacific
- Middle East
Reasons to Purchase this Report
• Current and future of global Coronary Artery Disease Therapeutics market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1799
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1799
Table of Content
Global Coronary Artery Disease Therapeutics Market Research Report
Section 1: Global Coronary Artery Disease Therapeutics Industry Overview
Section 2: Global Economic Impact on Coronary Artery Disease Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Coronary Artery Disease Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Coronary Artery Disease Therapeutics Market Forecast
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027